S. 272 (119th)Bill Overview

Protect Infant Formula from Contamination Act

Health|Child healthCongressional oversight
Cosponsors
Support
Democratic
Introduced
Jan 28, 2025
Discussions
Bill Text
Current stageCommittee

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Introduced
Committee
Floor
President
Law
Congressional Activities
01 · The brief
Plain-English summaryWhat this bill actually does

<p><strong>Protect Infant Formula from Contamination Act</strong></p><p>This bill imposes certain new requirements on infant formula manufacturers and the Food and Drug Administration (FDA) following the discovery of contaminated, adulterated, or misbranded infant formula.&nbsp;</p><p>Specifically, the bill requires infant formula manufacturers to report to the&nbsp;FDA&nbsp;within one business day of learning that formula that was&nbsp;processed by the manufacturer but that is&nbsp;no longer within the manufacturer’s control may not provide required nutrients or may be otherwise adulterated or misbranded.&nbsp;</p><p>Further, if any testing of finished infant formula reveals the presence of specified microorganisms (e.g., salmonella), the manufacturer must notify the FDA&nbsp;within one business day. (Under current law, manufacturers are only required to report contamination to the FDA&nbsp;if the affected formula has left the manufacturer’s control.) The manufacturer must also promptly provide the test results to the FDA and consult with the FDA on proper isolation and disposal of the affected product. The FDA must respond to such a notification and begin discussing proper investigative and corrective action with the manufacturer within one business day.&nbsp;</p><p>Within 90 days of a report of adulterated, misbranded, or contaminated infant formula, the FDA must determine whether the manufacturer that reported the problem has performed, or is performing, appropriate investigative and corrective action.&nbsp;</p><p>Finally, the FDA is required to periodically report on the infant formula supply chain and efforts to improve the safety and supply of infant formula, and must consult with other federal agencies and infant formula stakeholders on these issues. &nbsp;</p>

Why people may split

The main political fault lines are not fully surfaced yet, so coalition durability is still unclear.

Watch point

The next hurdle is converting committee movement into a floor coalition.

<p><strong>Protect Infant Formula from Contamination Act</strong></p><p>This bill imposes certain new requirements on infant formula manufacturers and the Food and Drug Administration (FDA) following the discovery of contaminated, adulterated, or misbranded infant formula.&nbsp;</p><p>Specifically, the bill requires infant formula manufacturers to report to the&nbsp;FDA&nbsp;within one business day of learning that formula that was&nbsp;processed by the manufacturer but that is&nbsp;no longer within the manufacturer’s control may not provide required nutrients or may be otherwise adulterated or misbranded.&nbsp;</p><p>Further, if any testing of finished infant formula reveals the presence of specified microorganisms (e.g., salmonella), the manufacturer must notify the FDA&nbsp;within one business day. (Under current law, manufacturers are only required to report contamination to the FDA&nbsp;if the affected formula has left the manufacturer’s control.) The manufacturer must also promptly provide the test results to the FDA and consult with the FDA on proper isolation and disposal of the affected product.

The FDA must respond to such a notification and begin discussing proper investigative and corrective action with the manufacturer within one business day.&nbsp;</p><p>Within 90 days of a report of adulterated, misbranded, or contaminated infant formula, the FDA must determine whether the manufacturer that reported the problem has performed, or is performing, appropriate investigative and corrective action.&nbsp;</p><p>Finally, the FDA is required to periodically report on the infant formula supply chain and efforts to improve the safety and supply of infant formula, and must consult with other federal agencies and infant formula stakeholders on these issues. &nbsp;</p>

Passage38/100

This bill has moved beyond introduction, but committee and floor dynamics still determine whether it can build durable support.

CredibilityPartial

How solid the drafting looks.

Contention62/100

The main political fault lines are not fully surfaced yet, so coalition durability is still unclear.

02 · What it does

Who stands to gain, and who may push back.

Likely benefits vs burdens0% / 100%
Likely helpedLikely burdened

These are examples from the analysis, not a ranked list of the most-affected groups.

Likely helped
  • No clear beneficiaries surfaced yet.
Likely burdened
  • No clear downsides surfaced yet.
03 · Why people split

Why the argument around this bill splits.

The main political fault lines are not fully surfaced yet, so coalition durability is still unclear.
Progressive

The main political fault lines are not fully surfaced yet, so coalition durability is still unclear.

Unclear
Centrist

The main political fault lines are not fully surfaced yet, so coalition durability is still unclear.

Unclear
Conservative

The main political fault lines are not fully surfaced yet, so coalition durability is still unclear.

Unclear
04 · Can it pass?

The path through Congress.

Introduced

Reached or meaningfully advanced

Committee

Reached or meaningfully advanced

Floor

Still ahead

President

Still ahead

Law

Still ahead

Passage likelihood38/100

This bill has moved beyond introduction, but committee and floor dynamics still determine whether it can build durable support.

Why this could stall
  • The next hurdle is converting committee movement into a floor coalition.
05 · Recent votes

Recent votes on the bill.

No vote history yet

The bill has not accumulated any surfaced votes yet.

06 · Go deeper

Go deeper than the headline read.

Included on this page

The main political fault lines are not fully surfaced yet, so coalition durability is still unclear.

This bill has moved beyond introduction, but committee and floor dynamics still determine whether it can build durable support.

Unlocked analysis

Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Protect Infant Formula from Contamination Act.

Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.

Perspective breakdownsPassage barriersLegislative design reviewStakeholder impact map
Open full analysis